Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Source: View publication →
In adults with early type 2 diabetes and elevated cardiovascular risk, the DPP-4 inhibitor linagliptin was noninferior to the sulfonylurea glimepiride regarding major adverse cardiovascular events, but offered significant benefits in reducing hypoglycemia and preventing weight gain.
Key Findings
Study Design
Study Limitations
Clinical Significance
CAROLINA provides critical head-to-head evidence that the sulfonylurea glimepiride does not increase cardiovascular risk compared to a modern DPP-4 inhibitor. This reassures clinicians who utilize sulfonylureas as a cost-effective second-line therapy. However, the dramatically lower incidence of hypoglycemia and the absence of weight gain strongly favor linagliptin as a safer alternative in patients where cost is not the primary barrier, particularly for frail patients, the elderly, or those operating heavy machinery where hypoglycemia poses severe risks.
Historical Context
Following the rosiglitazone controversy, the FDA mandated in 2008 that all new type 2 diabetes medications demonstrate cardiovascular safety. Most subsequent cardiovascular outcome trials (CVOTs) compared new agents against placebo (e.g., SAVOR-TIMI 53, EMPA-REG OUTCOME, LEADER). CAROLINA stands out as a unique active-comparator trial. Furthermore, it directly addressed a 50-year-old debate stemming from the 1970 University Group Diabetes Program (UGDP) study, which first raised alarms regarding the cardiovascular safety of sulfonylureas. Together with CARMELINA (which established linagliptin's safety versus placebo), CAROLINA definitively mapped the comparative safety landscape of DPP-4 inhibitors and modern sulfonylureas.
Guided Discussion
High-yield insights from every perspective
How do the mechanisms of action of linagliptin and glimepiride explain the significant difference in hypoglycemia and weight changes observed in the CAROLINA trial?
Key Response
Glimepiride is a sulfonylurea that binds to the SUR1 receptor on pancreatic beta cells, causing continuous, glucose-independent insulin release, which inherently risks hypoglycemia and promotes weight gain. Linagliptin is a DPP-4 inhibitor that prevents the breakdown of incretins like GLP-1 and GIP; these hormones stimulate insulin secretion only in a glucose-dependent manner, thereby minimizing hypoglycemia risk and remaining weight-neutral.
Given the noninferiority in cardiovascular outcomes but superiority in side effect profile for linagliptin demonstrated in CAROLINA, in which specific clinical scenarios would you still consider prescribing a sulfonylurea like glimepiride for a patient with type 2 diabetes?
Key Response
While DPP-4 inhibitors have a safer profile regarding hypoglycemia and weight, sulfonylureas remain highly efficacious for rapid glycemic lowering and are significantly cheaper. A resident must weigh the side effect profile against socioeconomic factors, utilizing glimepiride in patients where medication cost or insurance coverage is a major barrier to adherence, provided the patient is counseled on hypoglycemia management.
How does the CAROLINA trial's selection of an active comparator (glimepiride) rather than placebo contextualize the cardiovascular safety of both DPP-4 inhibitors and sulfonylureas, particularly when contrasted with the cardiovascular benefits seen with SGLT2 inhibitors and GLP-1 receptor agonists?
Key Response
CAROLINA proved that a modern sulfonylurea does not increase CV risk compared to a DPP-4 inhibitor, helping to debunk older fears (stemming from the UGDP study) about SU-induced CV mortality. However, it also highlights that unlike SGLT2is or GLP-1 RAs which demonstrate active cardiovascular risk reduction, DPP-4is and SUs merely possess neutral cardiovascular safety, reinforcing the preferential use of the former in high-risk patients.
The CAROLINA trial challenges historical dogma regarding the cardiovascular danger of sulfonylureas. How should this trial change your approach to deprescribing or maintaining glimepiride in older, stable patients who are not experiencing hypoglycemia?
Key Response
Attendings often face pressure to deprescribe sulfonylureas due to historical fears of cardiovascular harm and hypoglycemia. CAROLINA provides reassurance that in established, stable patients without a history of hypoglycemia, glimepiride is cardiovascularly safe, allowing for a more nuanced, patient-centered approach that avoids unnecessarily disrupting a well-tolerated, cost-effective regimen.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CAROLINA trial utilized an active-comparator, non-inferiority design with a pre-specified non-inferiority margin of 1.3 for the hazard ratio. What are the methodological vulnerabilities of this design regarding assay sensitivity, and how does the constancy assumption affect the interpretation of the results?
Key Response
Using an active comparator assumes the comparator has a known, stable effect (constancy assumption) compared to placebo. Establishing assay sensitivity is challenging without a placebo arm, as the trial must rely on historical data to ensure that neither drug is worse than a putative placebo. If both drugs were equally harmful or equally ineffective, non-inferiority could still be met, which requires rigorous statistical justification of the chosen margin.
Given the relatively long median follow-up of over 6 years in the CAROLINA trial, how does the differential rate of medication discontinuation and the introduction of unblinded, off-protocol rescue medications (such as SGLT2is or GLP-1 RAs) threaten the internal validity of the intention-to-treat analysis for the primary MACE endpoint?
Key Response
Over a prolonged follow-up, patients often require therapy escalation. If one arm preferentially receives modern cardioprotective agents as rescue therapy due to worse glycemic control or side effects, the intention-to-treat analysis could be biased toward the null, masking a true difference in MACE. Peer reviewers must heavily scrutinize the balance and timing of rescue medications to ensure the outcome reflects the randomized drugs.
In light of the CAROLINA trial demonstrating cardiovascular safety but no cardiovascular benefit for both linagliptin and glimepiride, how should current ADA/EASD guidelines position these two drug classes in the treatment algorithm for patients with high ASCVD risk versus those primarily requiring cost-effective interventions?
Key Response
Current ADA guidelines prioritize SGLT2is and GLP-1 RAs for patients with ASCVD due to proven benefit. CAROLINA reinforces that DPP-4is and SUs should not be used for CV risk reduction (providing Level A evidence for neutrality). However, it directly informs guidelines that when cost is a major barrier, SUs are a safe alternative for glycemic control without conferring excess cardiovascular risk, validating their position in cost-conscious guideline algorithms.
Clinical Landscape
Noteworthy Related Trials
SAVOR-TIMI 53 Trial
Tested
Saxagliptin 5mg or 2.5mg daily
Population
T2DM patients with a history of or risk for CV events
Comparator
Placebo
Endpoint
3-point MACE
TECOS Trial
Tested
Sitagliptin 100mg or 50mg daily
Population
T2DM patients and established cardiovascular disease
Comparator
Placebo
Endpoint
4-point MACE
CARMELINA Trial
Tested
Linagliptin 5mg daily
Population
T2DM patients with high CV and renal risk
Comparator
Placebo
Endpoint
3-point MACE
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis